| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 155 | / | 2013 | ||||||||
| Date of issue: | 2013-12-12 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Current report 155 buy back 12122013 | |||||||||||
| Official market - legal basis | |||||||||||
| Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| SOPHARMA AD (the “Company") hereby informs that from 5 December 2013 up to and including 11 December 2013 the Company bought 9 796 own shares representing 0.007% of the share capital of the Company, to the total value of 35 659.97 BGN on the Bulgarian Stock Exchange. The average price per share was 3.64 BGN. The shares have been bought on the basis of decision No. 7 of the Annual General Meeting of Shareholders from 23 June 2010. The total number of treasury shares after these transactions is 5 432 858, representing 4.12% of the share capital of the Company. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| Current report 155 buy back 12122013.doc | Current report 155 buy back 12122013 | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2013-12-12 | Ognian Donev | Executive director | |||
